Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain

Author:

Nieto‐Cid María12ORCID,Garriga‐Baraut Teresa3ORCID,Plaza‐Martín Ana Mª.4,Tortajada‐Girbés Miguel567ORCID,Torres‐Borrego Javier8ORCID,Lozano‐Blasco Jaime4,Moreno‐Galarraga Laura9ORCID,del Mar Folqué‐Giménez Mª.4,Bosque‐García Montse10ORCID,Gaboli Mirella11ORCID,López‐Neyra Alejandro12ORCID,Rivas‐Juesas Cristina13ORCID,Caballero‐Rabasco Mª. Araceli14ORCID,Freixa‐Benavente Andrea3ORCID,Valdesoiro‐Navarrete Laura10ORCID,de Mir‐Messa Inés3ORCID,Ballester‐Asensio Esther56,Penín‐Antón María15,Romero‐García Raquel16,Navarro‐Morón Juan17,Valenzuela‐Soria Alfredo18ORCID,Sánchez‐Mateos Mercedes19ORCID,Batlles‐Garrido José20,Sanz‐Santiago Verónica21ORCID,de Atauri Álvaro Gimeno‐Díaz22ORCID,Andrés‐Martín Anselmo23ORCID,Campos‐Alonso Elena24,Gómez‐Pastrana David25ORCID,Vázquez‐Rodríguez Elena26,Martínez‐Pardo Luz27,del Río‐Camacho Genoveva28ORCID,Mazón‐Ramos Ángel1ORCID,Nieto‐García Antonio1ORCID

Affiliation:

1. Pediatric Pulmonology and Allergy Unit Hospital Universitari i Politècnic La Fe, Health Research Institute La Fe Valencia Spain

2. Allergy Service Hospital Universitario de La Plana Villarreal Spain

3. Pediatric Allergy Unit, Hospital Universitari Vall d'Hebron. Grup d'Investigació “Creixement i Desenvolupament” Institut de Recerca de l'Hospital Universitari Vall d'Hebron (VHIR) Barcelona Spain

4. Allergy and Clinical Immunology Department Hospital Materno‐Infantil Sant Joan de Déu Barcelona Spain

5. Pediatric Allergy and Pneumology Unit Hospital Universitari Dr. Peset Valencia Spain

6. Department of Pediatrics, Obstetrics and Gynecology University of Valencia Valencia Spain

7. Pediatric Pulmonology and Allergy Unit Hospital Universitari i Politècnic La Fe Valencia Spain

8. Pediatric Allergy and Pulmonology Unit Hospital Universitario Reina Sofía Córdoba Spain

9. Pediatric Pulmonology Unit Complejo Hospitalario de Navarra. IdiSNA Health Research Institute Pamplona Spain

10. Pediatric Allergy and Pulmonology Unit Hospital de Sabadell – Corporació Universitaria Parc Taulí Sabadell Spain

11. Pediatric Pulmonology and Allergy Unit Hospital Universitario Virgen del Rocío Sevilla Spain

12. Pediatric Pulmonology Unit Hospital Universitario Ramón y Cajal Madrid Spain

13. Pediatric Pulmonology and Allergy Unit Hospital de Sagunto Sagunto Spain

14. Pediatric Pulmonology and Allergy Unit Hospital del Mar Barcelona Spain

15. Pediatrics Service Hospital Universitario Príncipe de Asturias Alcalá de Henares Spain

16. Pediatric Pulmonology and Allergy Unit Hospital Universitario Clínico San Cecilio Granada Spain

17. Pediatrics Service Hospital Costa del Sol Marbella Spain

18. Pediatric Pulmonology Unit Hospital Universitario Virgen de las Nieves Granada Spain

19. Pediatric Pulmonology Unit Hospital Universitario Puerta de Hierro Majadahonda Spain

20. Pediatric Pulmonology and Allergy Unit Hospital Universitario Torrecárdenas Almería Spain

21. Pediatric Pulmonology Unit Hospital Universitario Infantil Niño Jesús Madrid Spain

22. Pediatric Pulmonology and Allergy Unit Hospital Universitario 12 de Octubre Madrid Spain

23. Pediatric Pulmonology Unit Hospital Universitario Virgen Macarena Sevilla Spain

24. Pediatrics Service Hospital Comarcal Virgen de la Merced Osuna Spain

25. Pediatrics Service Hospital Universitario de Jerez de la Frontera Jerez de la Frontera Spain

26. Pediatric Pulmonology Unit Hospital Universitario Nuestra Señora de Valme Sevilla Spain

27. Pediatric Pulmonology Unit Complejo Hospitalario de Jaén Jaén Spain

28. Pediatrics Service Hospital Universitario Fundación Jiménez Díaz Madrid Spain

Abstract

AbstractBackgroundSevere pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost‐effective.MethodsA sample of 426 children with SPAA from the ANCHORS (Asthma iN CHildren: Omalizumab in Real‐life in Spain) study was used to calculate the incremental cost‐effectiveness ratio (ICER) for the avoidance of moderate‐to‐severe exacerbations (MSE) and also for the improvement in childhood Asthma Control Test (c‐ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data on health encounters and drug consumption before and up to 6 years after the beginning of the treatment with omalizumab.ResultsThe ICER per avoided MSE was €2107 after 1 year, and it consistently decreased to €656 in those followed up to 6 years. Similarly, the ICER for the minimally important difference in control tests showed a decrease from €2059 to €380 per each 0.5 points of improvement in ACQ5 and from €3141 to €2322 per each 3 points improvement in c‐ACT, at years 1 and 6, respectively.ConclusionThe use of OMZ is a cost‐effective option for most children with uncontrolled SPAA, especially those who have frequent exacerbations; the costs are progressively reduced in successive years of treatment.

Publisher

Wiley

Subject

Immunology,Immunology and Allergy,Pediatrics, Perinatology and Child Health

Reference41 articles.

1. GINA committee.Global strategy for asthma management and prevention 2022 update. Global Initiative for Asthma. 2022. p. 225.http://www.ginasthma.org. Accessed November 4 2022.

2. Evaluation of cost of disease: Assessing the burden to society of asthma in children in the European Union

3. CIHI.Asthma Hospitalizations Among Children and Youth in Canada: Trends and Inequalities — Chartbook 2018.https://www.cihi.ca/sites/default/files/document/asthma‐hospitalization‐children‐2018‐chartbook‐en‐web.pdf. Accessed November 4 2022.

4. The economic burden of severe asthma in children: a comprehensive study

5. Cost-of-illness studies: concepts, scopes, and methods

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3